Skip to Content
Merck
CN

SML0050

CGP 37849

≥98% (HPLC)

Synonym(s):

(3E)-2-Amino-4-methyl-5-phosphono-3-pentanoic acid

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

Empirical Formula (Hill Notation):
C6H12NO5P
CAS Number:
Molecular Weight:
209.14
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI

1S/C6H12NO5P/c1-4(3-13(10,11)12)2-5(7)6(8)9/h2,5H,3,7H2,1H3,(H,8,9)(H2,10,11,12)/b4-2+

SMILES string

C\C(CP(O)(O)=O)=C/C(N)C(O)=O

InChI key

BDYHNCZIGYIOGJ-DUXPYHPUSA-N

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

H2O: ≥2 mg/mL (warmed)

storage temp.

2-8°C

Quality Level

Application

CGP 37849 may be used in NMDA-mediated cell signaling studies.

Biochem/physiol Actions

CGP 37849 induces phencyclidine-like behavioral syndrome in amygdala-kindled rats that includes ataxia, locomotion and stereotypies.
CGP 37849 is a potent orally active competitive NMDA antagonist and anticonvulsant.
Potent orally active competitive NMDA antagonist and anticonvulsant.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

A Y Gemperle et al.
Neuroscience, 117(3), 681-695 (2003-03-06)
The mode of action of the antipsychotic drugs clozapine, haloperidol and iloperidone was investigated in layer V of prefrontal cortex slices using extracellular field potential, intracellular sharp-electrode as well as whole-cell voltage clamp recording techniques. Intracellular investigations on a broad
K Wedzony et al.
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 56(2), 205-221 (2005-06-30)
Malfunction of glutamatergic neurotransmission in postnatal period is considered to be a risk factor for development of schizophrenia. Thus, the present study investigates the impact of NMDA receptor blockade in the postnatal period on the density of tyrosine hydroxylase immunoreactive
Krzysztof Wedzony et al.
Pharmacological reports : PR, 60(6), 856-864 (2009-02-13)
Postnatal hypofunction of N-methyl-D-aspartate (NMDA) receptors leads to several behavioral deficits in adult rats resembling deficits typical of schizophrenia-like deficits of sensorimotor gating. Thus far, it is not known whether the above disruptions are sensitive to neuroleptic drugs. In order
Małgorzata Dybała et al.
Journal of neural transmission (Vienna, Austria : 1996), 115(11), 1519-1520 (2008-10-08)
The NMDA receptor antagonist, CGP 37849-induced reduction in immobility time in the forced swim test in mice was not antagonized by pre-treatment with the AMPA receptor antagonist NBQX. This is the first demonstration of the antidepressant effect of the NMDA
K Wedzony et al.
Neuroscience, 153(4), 1370-1379 (2008-04-25)
The malfunction of glutamatergic neurotransmission in the neonatal or postnatal periods may be a risk factor for the appearance of neuroanatomical, neurochemical or functional changes that are characteristic of schizophrenia. Thus, the present study was undertaken to investigate whether blockade

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service